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ABSTRACT
Objectives: The MUSICIAN study has previously
shown short-term benefit but only marginal cost-
effectiveness for two non-pharmacological
interventions for chronic widespread pain (CWP). We
wished to determine their long-term effectiveness and
cost-effectiveness.
Methods: A 2×2 factorial randomised controlled trial
based in primary care in the UK. People were eligible if
they were aged ≥25 years with CWP for which they
had consulted their general practitioner. The
interventions were a 6-month telephone cognitive
behaviour therapy (tCBT) and/or a tailored exercise
programme, in comparison to usual care. The primary
outcome was patient-reported change in health.
Results: 884 persons were eligible, 442 were
randomised and 81.7% were followed up 24 months
post-treatment. In comparison to usual care (positive
outcome 12.8%), tCBT (35.4%; OR 3.7 95% CI (1.8 to
8.0)), exercise (29.3%; OR 2.8 95% CI (1.3 to 6.0))
and both interventions (31.2%; OR 3.1 95% CI (1.3 to
6.0)) were significantly more effective. There was only
a small decrease in effectiveness over time for
individual and combined treatments. Those with more
intense/disabling pain, higher distress and those who
exhibited passive coping at baseline were more likely to
have a positive outcome with tCBT than persons
without these characteristics. tCBT was associated with
the greatest increase in quality of life and lowest costs.
Cost per quality adjusted life year was £3957–£5917
depending on method of analysis.
Conclusions: A short course of tCBT for people with
CWP was effective long-term and was highly cost-
effective. Exercise was also effective but delivered
positive outcome for fewer patients at greater cost, and
there was no advantage for patients receiving both
interventions.
Trial registration number: ISRCTN67013851.
BACKGROUND
Chronic widespread pain (CWP: deﬁned as
axial skeleton pain and contra-lateral body
pain present for at least 3 months) has a
population prevalence of 11–14%.1 CWP is
the cardinal feature of ﬁbromyalgia, one of
the most common reasons for referral to a
rheumatologist.2 Longitudinal studies of
CWP and ﬁbromyalgia demonstrate that
symptoms are persistent and long-lasting. In
an 11-year follow-up of 1555 patients with
Key messages
▸ Telephone cognitive behaviour therapy (tCBT)
and exercise have been shown in systematic
reviews to be associated with short-term
improvement of fibromyalgia symptoms,
although the size of effects are modest.
▸ 6-month programmes of CBT delivered by tele-
phone and exercise were associated with health
improvement 2 years after the end of treatment,
although there was no additional benefit of
receiving both treatments.
▸ tCBT was highly cost-effective and improvement
could partly be predicted by patient characteristics.
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ﬁbromyalgia in the USA, substantial or moderate
symptom improvement was observed in only 10% and
15% patients, respectively, while in 39%, symptoms wor-
sened.3 In a follow-up of 173 adults with CWP in the UK
only 15% were pain-free 7 years later.4
Although CWP symptoms are sometimes described as
‘unexplained’, epidemiological studies over the past two
decades have provided important information on aeti-
ology that has informed studies of management.
Consistent ﬁndings in longitudinal population studies
are that persons with poorer mental health (anxiety,
depression and general psychological distress) and who
take low levels of exercise have an increased risk of
developing CWP or ﬁbromyalgia.5–7 These risk factors
offer targets for intervention: Bernardy et al8 concluded
that cognitive behaviour therapy (CBT) resulted in
increased coping with pain, reduced depressed mood
and healthcare seeking behaviour; Haüser et al9
reported that an aerobic exercise programme resulted
in decreased pain, and had positive effects on mood,
health-related quality of life and physical ﬁtness; and a
network meta-analysis reported improved patient out-
comes for both CBT and aerobic exercise.10 However, in
a recent Cochrane review of CBT for ﬁbromyalgia, the
median duration of post-treatment follow-up for CBT
interventions evaluated in trials was only 6 months
post-treatment.11
We have previously reported the short-term (3 months
post-treatment) results of the ‘Managing Unexplained
Symptoms (chronic widespread pain) In primary Care:
Involving traditional and Accessible New approaches’
(MUSICIAN) trial.12 These demonstrated signiﬁcant
clinical beneﬁts of an individual or combined 6-month
programme of CBT delivered by telephone (tCBT) and
an exercise programme, compared with usual care.
However, cost-effectiveness of the active interventions
was marginal at 3 months post-treatment. In view of the
positive clinical results we decided to conduct a long-
term (24 months post-treatment), unplanned, follow-up
to determine whether clinical beneﬁts persisted, and to
assess longer term cost-effectiveness. We also aimed to
determine whether the characteristics of participants at
trial entry predicted treatment response.
METHODS
A 2×2 factorial randomised controlled trial was con-
ducted during 2008–2012. Trial participants, identiﬁed
from the registered populations of eight general practices
in Aberdeen, Scotland, and in Cheshire, England, were
people aged ≥25 years who reported CWP according to
the deﬁnition in the American College of Rheumatology
(ACR) 1990 criteria for ﬁbromyalgia,13 and for which
they had consulted their general practitioner (GP) in the
previous year. Exclusion criteria included contraindica-
tions to exercise, having pain that required speciﬁc alter-
native treatment or not having access to a landline
telephone (for the delivery of CBT). Comorbid
rheumatic disease was not an exclusion criterion.
Participants were electronically randomised to treatment
groups in blocks, stratiﬁed by pain intensity and disability
(Chronic Pain Grade (CPG) questionnaire14) and psy-
chological distress (General Health Questionnaire 12
item version (GHQ)15) A full description of those rando-
mised into the trial has been reported previously.12
Treatment groups
Telephone-delivered BCBT
This was delivered by therapists accredited by the British
Association for Behaviour and Cognitive Psychotherapies
who received 3 days of trial-speciﬁc training, a therapist
manual and fortnightly clinical supervision. All sessions
were digitally recorded for use in therapist supervision.
Therapists mailed brief details welcoming patients to the
study, giving a brief introduction to CBT and providing
contact details. The intervention included an initial
assessment (45–60 min), seven weekly sessions (each
30–45 min) delivered over 6 weeks, and a single session
at 3 and 6 months postrandomisation. Therapists con-
ducted a patient-centred assessment, developed shared
understanding and formulation of the participants’
problem(s), and identiﬁed two to three patient-deﬁned
goals. Patients received a self-management CBT manual,
‘Managing Chronic Widespread Pain’, developed for the
study (available from the authors). To enable patients to
make an informed choice of the form of CBT they pre-
ferred, the manual included stories of ﬁctitious patients
using speciﬁc CBT techniques: behavioural activation
(structured increasing of activities), cognitive restructur-
ing (identifying and evaluating unhelpful thinking
styles) and lifestyle changes (managing sleep, fatigue,
irritability). Sessions involved implementing CBT techni-
ques, working toward goals and problem solving barriers
to improvement, while later sessions focused on relapse
prevention.
Exercise
Experienced ﬁtness instructors delivered the intervention
and received a 1-day training session on exercise prescrip-
tion for patients with CWP. They were observed during
induction and follow-up meetings to monitor protocol
adherence. Patients received a leisure-facility gym-based
exercise programme consistent with American College of
Sport Medicine (ACSM) guidelines for improving cardio-
respiratory ﬁtness.16 Following an induction session,
patients were offered six ﬁtness instructor-led monthly
appointments for programme reassessment. Exercise
intensity increased until levels were sufﬁcient to achieve
40–85% of heart rate reserve. The ACSM does not pre-
scribe speciﬁc exercises; these are negotiated between
ﬁtness instructor and patient. The trial protocol reﬂected
this, allowing exercises to be changed while maintaining
the goal of improving cardiorespiratory ﬁtness. The exer-
cise intensity range was broad, allowing individuals with
low ﬁtness or those who were deconditioned to achieve
goals with low-intensity exercise. To avoid musculoskeletal
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injuries and to promote compliance, initial intensity was
low to moderate. Patients were free to engage in add-
itional exercises (eg, strength and ﬂexibility training) to
those prescribed. The recommended session duration
was 20–60 min. Patients completed a diary recording fre-
quency of gym attendance, exercise duration and type of
exercise, which was returned to the coordinating unit.
The ACSM guidelines recommend an exercise frequency
of 3–5 days per week. This was thought to be unrealistic.
Instead, patients were advised to attend at least twice a
week, and on non-gym days engage in ‘everyday’ activities
(eg, brisk walking) to enhance cardiorespiratory ﬁtness.
Combined treatment
Participants randomised to this group received both of
the above treatments concurrently.
Treatment as usual
Participants randomised to this group continued to
receive usual care (without any restrictions) from their GP.
Outcome measurements
Primary and secondary outcome data were collected at
the end of treatment, and at 3 and 24 months post-
treatment, by postal questionnaire. Non-responders were
followed up with telephone interviews in which the
primary outcome measure was recorded. The primary
outcome measure was self-reported change in health
status since the start of the trial; on a 7 point scale
ranging from ‘Very much worse’ through ‘No change’ to
‘Very much better’. A positive outcome was deﬁned as a
report of ‘Much better’ or ‘Very much better’. This
measure has been used previously in trials of exercise
for ﬁbromyalgia17 and for chronic fatigue syndrome.18
Secondary outcome measures were the Chalder
Fatigue Scale,19 20 pain (measured by the CPG), the
Vanderbilt Pain Management Inventory,21 psychological
distress (measured by the GHQ), the Sleep Problem
Scale,22 the Tampa Scale for Kinesiophobia23 and the
36-Item Short Form Health Questionnaire (SF36).24
Statistical issues: sample size and analysis
The sample size calculation in the registered protocol
was based on change in the primary outcome measure
at 3 months post-treatment. Anticipated improvements
in the four arms (taking account of likely effectiveness
and compliance with intervention) were: treatment as
usual (TAU) 10%, exercise only 20%, CBT only 21.3%,
exercise and CBT 31.3%. A total of 552 persons were
deemed necessary to have at least 80% power of detect-
ing differences in the active intervention groups com-
pared with TAU. However, due to higher than
anticipated follow-up rates during the trial, and the fact
that the trial steering committee and data monitoring
committee considered the original estimates (which
used a χ2 test with continuity correction) to be too strin-
gent, the trial sample size was reduced to 468.
Main treatment effects were assessed on an intention-
to-treat analysis. The primary outcome was analysed
using generalised estimating equations (GEE) for longi-
tudinal logistic regression. A 2-way factorial regression
using the outcome at end of treatment, 3 and
24 months post-treatment, including terms for treatment
interaction and treatment–time effect, was ﬁtted. The
term for the interaction of treatments was less than one
(ie, the combined effects were less than multiplica-
tive).12 Analysis was carried out, therefore, comparing
the three treatment groups to TAU. Secondary outcomes
were analysed using GEE for longitudinal ordinal or
linear regression where appropriate, including a treat-
ment by time interaction with four separate treatment
groups. Results are presented as ORs for logistic regres-
sion, proportional OR for ordinal regression and non-
standardised regression coefﬁcients for linear regression,
with 95% CI for each active treatment compared with
the TAU group at each time point, and for the treat-
ment by time interaction. A Bonferroni correction
allowed for multiple testing, with p values less than 0.004
considered statistically signiﬁcant. Analyses were adjusted
for age, sex, baseline CPG, baseline GHQ score and
study centre, with analyses of secondary outcomes also
adjusted for baseline scores on the outcome of interest.
In order to determine the inﬂuence of missing follow-up
data, we compared baseline data for participants who
did and did not provide 24-month follow-up data. We
also determined how sensitive the results were to
missing follow-up data by, conservatively, assuming that
all persons lost to follow-up data did not have a positive
outcome on the primary measure, as well as performing
analyses using imputation by chained equations, which
predicts missing data based on all available data. All ana-
lyses were conducted using STATA software.25
To determine predictors of effectiveness of each inter-
vention, logistic regression models were ﬁtted separately
for each outcome time point, to see which baseline
factors (if any) modiﬁed treatment effectiveness. Age
was treated as a continuous variable to calculate change
in odds of treatment effectiveness for every 10 years.
Other predictors were split into two categories by the
median value. Four treatment groups were speciﬁed and
models included an interaction between the baseline
characteristic of interest and the treatment. ORs were
calculated to compare the odds of improvement in each
active treatment group to TAU. Then, a separate longitu-
dinal model was ﬁtted for each of the predictors of treat-
ment effectiveness, to assess whether the effect was the
same over all follow-up time points. Adjustment was
made for the same baseline characteristics as in the
main analysis.
Health economic analysis
The UK national tariff26 was used to assign each partici-
pant with a health state utility weight based on their
response to the EQ-5D at 24 months post-treatment.
Reported health service resource use during the
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previous 6 months was valued using the same unit cost
data used in the original analysis.27–29 Additional quality
adjusted life years (QALYs) accrued between 3 and
24 months post-treatment were calculated for each par-
ticipant assuming a linear change in utility. This was
added to the 3-month post-treatment QALY estimate for
each patient. Linear interpolation between reported
health service costs at 3 and 24 months post-treatment
was used to impute an average quarterly cost for each
patient for each of the ﬁve quarters not covered by data
collection.30 Costs and QALYs incurred beyond
12 months were discounted at the rate of 3.5% per
annum in line with accepted practice in the UK.
Multivariate regression analysis estimated differences in
mean costs and QALYs between the three active treat-
ment groups and TAU. A generalised linear model, with
a γ family distribution and a log link function, was speci-
ﬁed to account for the skewed nature of the cost data.
Cost-effectiveness acceptability curves were constructed
using non-parametric bootstrapping and the net monet-
ary beneﬁt framework, to determine the probability of
the alternative interventions being considered cost-
effective at different ceiling ratios representing society’s
willingness to pay (WTP) per QALY (£20 000–£30 000
per QALY are commonly applied ceiling ratios in the
UK). The analysis was initially conducted for participants
with complete cost and QALY data at ﬁnal follow-up.
Multiple imputation analyses, using chained equations,
were used to assess the sensitivity of ﬁndings to missing
data.
RESULTS
In total, 884 people were identiﬁed as eligible and invited
to participate in the trial, and 442 (50%) were rando-
mised (ﬁgure 1). Those randomised had a mean age of
56.2 years (range 25–85 years), 69.5% were women and
33.9% were in full-time employment. The CWP was
graded as CPG III-IV for 30% of participants. In compari-
son to all those identiﬁed as eligible, those randomised
were more likely to be older, have a higher body mass
index and have more severe pain (p<0.05), with no other
differences found (table 1). There was no important or
statistically signiﬁcant difference in any of the secondary
outcome measures across treatment groups.12
Primary outcome
At 24 months post-treatment, 361 participants were fol-
lowed up (81.7%). Of these, 12.8% in the TAU group
reported a positive outcome compared with 35.4% in
the tCBT group, 29.3% in the exercise group and 31.2%
in the combined treatment group (table 2). The
adjusted OR for reporting a positive outcome compared
with the TAU group were tCBT OR 3.6 (95% CI 1.7 to
7.6), exercise 2.5 (95% CI 1.2 to 5.4) and combined
treatment 2.9 (95% CI 1.4 to 6.0).
Each treatment group was associated with statistically
signiﬁcant increased odds of a positive outcome at each
time point compared with TAU (table 3). The odds of
reporting a positive outcome showed a small decrease
with time for all active treatments (change in OR/
month 0.96 to 0.99).
Secondary outcomes
The active treatment groups were generally associated
with small improvements in each of the secondary mea-
sures compared with TAU (tables 4 and 5), but these
tended to decrease over time. At 24 months, participants
in the combined treatment group (in comparison to the
TAU group) had signiﬁcantly (p<0.004) reduced passive
coping, kinesiophobia and improved SF-36 role physical;
with signiﬁcant improvement in four other SF-36 sub-
scales that did not persist after correction for multiple
testing. The tCBT group showed signiﬁcant improve-
ment at 24 months (in comparison to the TAU group)
in passive coping, kinesiophobia, distress and SF-36
social function subscale but these did not persist after
correction for multiple testing. The exercise group
showed (in comparison to the TAU group) a signiﬁcant
improvement in SF-36 role emotional at 24 months that
did not persist after correction for multiple testing.
Influence of missing data
Comparing the baseline data of responders (n=361) and
non-responders (n=81) at 24 months post-treatment, the
latter were more likely to have had CPG IV (15.5% and
28.4%, respectively) but there were no other statistically
signiﬁcant, sizeable or clinically important differences in
demographic or clinical variables assessed. Assuming,
conservatively, that all participants who did not provide
outcome data at 24 months did not have a positive
primary outcome, the percentage of participants with a
positive outcome across the four groups was tCBT
25.9%, exercise 24.8%, combined intervention 25.9%,
TAU 11%. Differences between the intervention groups
and TAU remained statistically signiﬁcant (OR for posi-
tive outcome compared with usual care: tCBT (OR 2.8
(95% CI 1.4 to 5.9), exercise 2.7 (95% CI 1.3 to 5.6),
combined 2.8 (95% CI 1.4 to 5.9)). Imputation pro-
duced results that were very similar to those reported in
table 2, with any small differences not affecting the inter-
pretation of ﬁndings (data not shown).
Predictors of treatment effectiveness
Potential predictors of treatment effectiveness are shown
in table 6. Participants with more intense or disabling
pain (as measured by CPG) or higher levels of distress
(measured by GHQ) beneﬁtted more from tCBT or
combined treatment (compared to those without these
characteristics) and participants with higher levels of
kinesiophobia were more likely to beneﬁt from tCBT.
Health economics
Treatment costs during the intervention period, and
post-treatment follow-up costs, are summarised in
table 7. The cost-effectiveness analysis showed that all of
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Figure 1 MUSICIAN Trial CONSORT flow diagram (TAU, treatment as usual; tCBT, telephone cognitive behavioural therapy).
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the active treatments were associated with an increased
cost to the health service and an increase in QALYs com-
pared with TAU (table 8). tCBT was associated with the
lowest cost increase and highest QALY gain, and is there-
fore dominant over the alternative active treatments.
Based on analysis of persons who provided complete
data, the additional cost per QALY gained with tCBT
versus TAU was £5917. Based on the results of the non-
parametric bootstrap, tCBT was found to have an
approximately 75% chance of being the preferred strat-
egy at a ceiling ratio of £20 000 per QALY gained
(ﬁgure 2). The general pattern of results remained the
same with multiple imputation for missing data,
although the additional cost per QALY gained for tCBT
reduced to £3957.
DISCUSSION
We have shown that after a short-course of tCBT and/or
a personalised exercise programme, approximately
one-third of patients with CWP reported a positive
primary outcome (change in condition) 24 months after
end of treatment, signiﬁcantly better than patients
receiving TAU, where the improvement was one in
eight. tCBT and exercise appeared to be similarly beneﬁ-
cial, and there was no advantage gained from providing
both. Combined treatment, however, did appear to
produce greater improvements in several secondary
outcome measures 24 months post-treatment (compared
to usual care and after correction for multiple testing).
tCBT was highly cost-effective in the long-term, with the
cost per QALY ranging between approximately £4k and
£6k, depending on the method of analysis.
A number of points should be considered when inter-
preting our results. First, participants reported CWP
(rather than having a diagnosis of ﬁbromyalgia) and
were recruited through primary care. Thus, many in the
study population had symptoms that were less severe, as
evidenced by the CPG and reported work status, than
would typically be seen by rheumatologists. Second, it
could be argued that the positive results were due to
non-speciﬁc beneﬁts from participating in a trial rather
than the speciﬁc effects of the interventions delivered.
Supporting such an interpretation is the similarity of
positive effects across all active intervention groups
(including the group receiving both interventions).
Against this interpretation, CWP has proved very difﬁcult
for rheumatologists and others to treat, and so it seems
unlikely that such strongly positive improvements
resulted from simply ‘attention’. We also demonstrated
improvements in some of the secondary outcomes
related to participants’ perceptions of improvement in
their condition. If our initial results were due to non-
speciﬁc effects, we would expect such effects to wane
with time. Instead, we have observed persistence of
strong effects over 2 years. Furthermore, we have demon-
strated that persons more likely to beneﬁt from tCBT
have characteristics that tCBT seeks to change. We recog-
nise, however, that not all patients with CWP will neces-
sarily be willing to consider undertaking exercise or
participating in a CBT programme. Our results, there-
fore, can only be extrapolated to those willing to do so
and, in this study, 70% of persons randomised to tCBT
completed at least six sessions while 50% of persons ran-
domised to exercise attended the gym at least two times
per week. Third, the study was not powered to under-
take a robust analysis of those patients who might
beneﬁt most from each treatment. However, our strongly
positive results for the primary outcome, and given the
current interest in stratiﬁed medicine, provide an indica-
tion of those persons with CWP who may be most likely
to beneﬁt. This may be helpful given that CBT is not
available everywhere in the UK or elsewhere. Finally, we
did not restrict the usual care provided by the GP.
However, no participant in the TAU arm reported receiv-
ing ‘talking therapy’ or exercise therapy at follow-up.
With no pharmacological therapies licensed in the UK
for ﬁbromyalgia (of which CWP is the cardinal feature),
management is likely to have focused on advice, investi-
gation and management of speciﬁc reported symptoms.
Reviews of CBT have been conducted in patients with
ﬁbromyalgia, however, their conclusions are not com-
pletely consistent. Cochrane reviews agree that CBT
affects mood and pain positively.11 31 While our study
reported positive effects in the tCBT arm across all
primary and secondary measures 2 years after the end of
treatment, with statistically signiﬁcant improvements in
passive coping, kinesiophobia, distress and SF-36 social
Table 1 Baseline characteristics of participants (n=442)
Age*, years 56.3 (13.0)
Gender, female 307 (69.5)
Employment status
Working full-time 154 (34.8)
Working part-time 68 (15.4)
Retired 142 (32.1)
Other 78 (17.6)
Chronic Pain Grade
I 92 (20.8)
II 174 (39.4)
III 97 (22.0)
IV 79 (17.9)
GHQ* 3.2 (3.6)
EQ-5D* 0.69 (0.19)
SF-36*
Physical component 40.6 (7.9)
Mental component 45.2 (10.7)
Fatigue* 19.6 (5.9)
VPMI*
Passive coping 29.5 (7.3)
Active coping 24.9 (4.2)
Sleep scale* 9.2 (5.6)
Tampa Scale for Kinesiophobia* 35.8 (5.3)
Values are n (%) except * which are mean (SD).
GHQ, General Health Questionnaire; SF-36, 36-item Short Form
Health Questionnaire; VPMI, Vanderbilt Pain Management
Inventory.
6 Beasley M, et al. RMD Open 2015;1:e000026. doi:10.1136/rmdopen-2014-000026
RMD Open
group.bmj.com on December 14, 2015 - Published by http://rmdopen.bmj.com/Downloaded from 
Table 2 Primary and secondary outcomes at 24 months post-treatment
TAU
N=94
tCBT
N=82
Exercise
N=92
Combined
N=93
Primary outcome: global change in health since entering trial
Original data
Very much better 3 (3.2) 5 (6.1) 5 (5.4) 10 (10.8)
Much better 9 (9.6) 24 (29.3) 22 (23.9) 19 (20.4)
A little better 14 (14.9) 15 (18.3) 16 (17.4) 17 (18.3)
No change 31 (33.0) 21 (25.6) 22 (23.9) 19 (20.4)
A little worse 21 (22.3) 9 (11.0) 16 (17.4) 18 (19.4)
Much worse 7 (7.5) 8 (9.8) 9 (9.8) 10 (10.8)
Very much worse 9 (9.6) 0 2 (2.2) 0
Dichotomised outcome
Much better/very much better 12 (12.8) 29 (35.4) 27 (29.3) 29 (31.2)
Less than much better 82 (87.2) 53 (64.6) 65 (70.7) 64 (68.8)
Secondary outcomes
CPG
0—No pain 14 (19.4) 12 (18.2) 10 (14.1) 10 (13.5)
I—Low disability, low intensity 18 (25.0) 22 (33.3) 23 (32.4) 29 (39.2)
II—Low disability, high intensity 22 (30.6) 20 (30.3) 16 (22.5) 21 (28.4)
III—High disability, moderately limiting 11 (15.3) 8 (12.1) 15 (21.1) 8 (10.8)
IV—High disability, severely limiting 7 (9.7) 4 (6.1) 7 (9.9) 6 (8.1)
GHQ* 3.0 (3.3) 2.2 (3.4) 2.6 (3.7) 3.0 (3.7)
EQ-5D* 0.63 (0.32) 0.73 (0.24) 0.71 (0.24) 0.68 (0.24)
SF-36* (all 1–100)†
General health 56.2 (21.3) 60.4 (20.1) 59.9 (22.3) 61.5 (23.3)
Physical function 59.2 (31.9) 66.9 (26.8) 68.9 (25.9) 68.3 (24.8)
Role physical 59.7 (30.7) 63.3 (27.0) 62.9 (25.2) 68.4 (29.3)
Vitality 45.0 (22.1) 50.6 (21.9) 49.8 (20.0) 49.2 (22.8)
Social function 68.5 (28.2) 74.8 (26.3) 71.4 (26.1) 76.2 (25.5)
Role emotional 73.7 (27.3) 76.5 (26.4) 79.7 (23.2) 74.1 (29.3)
Fatigue (0–42)* 19.1 (7.3) 17.8 (6.6) 17.8 (5.8) 17.6 (6.9)
VPMI*
Passive coping (11–55) 29.4 (8.9) 25.8 (8.4) 27.5 (8.8) 25.3 (8.2)
Active coping (7–35) 24.5 (4.6) 25.2 (4.2) 25.1 (3.3) 25.8 (4.4)
Sleep scale*(0–20) 9.7 (5.9) 9.4 (6.0) 8.8 (5.2) 8.3 (6.0)
Tampa Scale for Kinesiophobia*(17–68) 36.2 (7.2) 33.3 (5.7) 34.1 (7.6) 32.9 (7.8)
Values are n (%) except * which are mean (SD).
†Bodily Pain scores not available due to printing error on questionnaire.
CPG, Chronic Pain Grade questionnaire; GHQ, General Health Questionnaire; SF-36, 36 item Short Form Health Questionnaire; TAU,
treatment as usual; tCBT, telephone cognitive behavioural therapy; VPMI, Vanderbilt Pain Management Inventory.
Table 3 Estimations of treatment effectiveness at end of treatment, 3 and 24 months post-treatment calculated from
longitudinal model (adjusted ORs*, 95% CIs and p values)
End of treatment 3 months post-treatment 24 months post-treatment Change in OR/month
tCBT 5.0 4.8 3.6 0.99
(2.4 to 10.6) (2.4 to 9.7) (1.7 to 7.6) (0.95 to 1.02)
<0.001 <0.001 0.001 0.410
Exercise 4.6 4.3 2.5 0.98
(2.2 to 9.6) (2.1 to 8.5) (1.2 to 5.4) (0.94 to 1.01)
<0.001 <0.001 0.015 0.147
Combined treatment 6.7 6.0 2.9 0.96
(3.3 to 13.9) (3.1 to 11.9) (1.4 to 6.0) (0.93 to 0.997)
<0.001 <0.001 0.006 0.035
*Results of the four-group longitudinal logistic regression model, adjusting for age, sex, centre, and baseline CPG and GHQ scores, including
a term for treatment–time interaction.
CPG, Chronic Pain Grade questionnaire; GHQ, General Health Questionnaire; tCBT, telephone cognitive behavioural therapy.
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Table 4 Treatment effectiveness, secondary outcomes (values are unstandardised coefficients except CPG, which are
proportional ORs)*
End of
treatment
3 months
post-treatment
24 months
post-treatment
Treatment–time
interaction (slope)
CPG
tCBT 0.4† 0.5† 0.7 1.02
(0.3 to 0.8) (0.3 to 0.8) (0.3 to 1.3) (0.99 to 1.05)
Exercise 0.7 0.8 1.3 1.02
(0.5 to 1.1) (0.5 to 1.2) (0.7 to 2.4) (0.99 to 1.05)
Combined treatment 0.5† 0.5‡ 0.9 1.03
(0.3 to 0.8) (0.3 to 0.8) (0.4 to 1.8) (1.00 to 1.06)
GHQ
tCBT −1.0‡ −1.0‡ −1.0‡ 0.00
(−1.8 to −0.3) (−1.8 to −0.3) (−1.9 to −0.1) (−0.03 to 0.04)
Exercise −0.9‡ −0.9‡ −0.5 0.02
(−1.7 to −0.2) (−1.6 to −0.2) (−1.4 to 0.3) (−0.02 to 0.05)
Combined treatment −1.0‡ −0.8‡ 0.0 0.04‡
(−1.7 to −0.2) (−1.5 to −0.1) (−0.9 to 0.9) (0.00 to 0.08)
Fatigue
tCBT −2.6‡ −2.4‡ −1.0 0.06
(−4.4 to −0.7) (−4.1 to −0.6) (−3.0 to 1.1) (−0.01 to 0.14)
Exercise −2.4‡ −2.2‡ −1.2 0.05
(−4.1 to −0.7) (−3.9 to −0.6) (−3.2 to 0.8) (−0.02 to 0.12)
Combined treatment −4.4† −4.0† −1.5 0.12†
(−6.1 to −2.6) (−5.7 to −2.3) (−3.5 to 0.5) (0.04 to 0.20)
VPMI passive coping
tCBT −2.0‡ −2.0‡ −2.7‡ −0.03
(−3.7 to −0.2) (−3.7 to −0.4) (−4.7 to −0.7) (−0.10 to 0.04)
Exercise −2.0‡ −2.0‡ −1.3 0.03
(−3.6 to −0.3) (−3.5 to −0.3) (−3.2 to 0.6) (−0.04 to 0.10)
Combined treatment −3.1† −3.1† −3.1† 0.00
(−4.7 to −1.5) (−4.7 to −1.5) (−5.0 to −1.2) (−0.07 to 0.07)
VPMI active coping
tCBT 0.8 0.8 0.8 0.00
(−0.1 to 1.7) (0.0 to 1.6) (−0.3 to 1.8) (−0.05 to 0.04)
Exercise 1.1‡ 1.1‡ 0.7 −0.02
(0.3 to 2.0) (0.3 to 1.9) (−0.3 to 1.8) (−0.06 to 0.03)
Combined treatment 1.3† 1.3† 0.8 −0.02
(0.5 to 2.1) (0.5 to 2.0) (−0.2 to 1.8) (−0.07 to 0.02)
Sleep problems
tCBT −1.8‡ −1.7‡ −0.8 0.04
(−3.0 to −0.6) (−2.8 to −0.5) (−2.3 to 0.6) (−0.02 to 0.10)
Exercise −1.2‡ −1.2‡ −0.9 0.01
(−2.4 to −0.1) (−2.3 to −0.1) (−2.3 to 0.5) (−0.04 to 0.07)
Combined treatment −1.5‡ −1.4‡ −0.8 0.03
(−2.6 to −0.3) (−2.5 to −0.2) (−2.2 to 0.6) (−0.03 to 0.08)
TSK
tCBT −1.4 −1.5 −1.9‡ −0.02
(−3.0 to 0.1) (−3.0 to 0.0) (−3.6 to −0.2) (−0.08 to 0.04)
Exercise −1.5 −1.4 −1.2 0.01
(−3.0 to 0.0) (−2.9 to 0.0) (−2.9 to 0.5) (−0.04 to 0.07)
Combined treatment −2.4† −2.5† −2.6† −0.01
(−3.9 to −1.0) (−3.9 to −1.0) (−4.3 to −0.9) (−0.06 to 0.05)
*Comparison group—treatment as usual. All models are adjusted for age, sex, centre, baseline CPG and GHQ scores, and baseline levels of
outcome of interest.
†p<0.004, with correction for multiple testing.
‡p<0.05.
CPG, Chronic Pain Grade questionnaire; GHQ, General Health Questionnaire; TAU, treatment as usual; tCBT, telephone cognitive
behavioural therapy; TSK, Tampa Scale for Kinesiophobia; VPMI, Vanderbilt Pain Management Inventory.
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function subscale (compared to TAU) at p<0.05, none
met the more stringent statistical signiﬁcance cut-off
after correction for multiple testing. Most of the evi-
dence to date on the effectiveness of exercise relates to
ﬁbromyalgia. Our study extends this evidence of beneﬁt
to persons with CWP and it provides evidence that the
beneﬁt is long-lasting. It has previously been shown that
the effects of an exercise programme on psychological
outcomes are maintained long after such a programme
has ﬁnished and that long-term improvements in
patients with ﬁbromyalgia due to increased physical
activity are maintained regardless of whether activity
levels return to pretreatment levels after active treatment
has ﬁnished.32 It has been demonstrated in a recent
meta-analysis that community-deliverable exercise pro-
grammes are effective for pain and physical function in
Table 5 Treatment effectiveness, secondary outcomes (SF-36*) (values are unstandardised coefficients)†
End of
treatment
3 months
post-treatment
24 months
post-treatment
Treatment–time
interaction (slope)
SF36—general health
tCBT 2.4 2.7 4.4 0.08
(−1.7 to 6.5) (−1.3 to 6.6) (−0.2 to 9.1) (−0.09 to 0.26)
Exercise 2.5 2.7 4.0 0.06
(−1.5 to 6.4) (−1.1 to 6.5) (−0.6 to 8.5) (−0.11 to 0.23)
Combined treatment 5.1‡ 5.1‡ 5.1‡ 0.00
(1.2 to 9.0) (1.3 to 8.9) (0.6 to 9.6) (−0.17 to 0.17)
SF36—physical function
tCBT 3.5 3.5 3.3 −0.01
(−0.9 to 7.9) (−0.8 to 7.7) (−1.7 to 8.3) (−0.19 to 0.17)
Exercise 6.4§ 6.2§ 4.7 −0.07
(2.2 to 10.6) (2.1 to 10.3) (−0.1 to 9.5) (−0.24 to 0.10)
Combined treatment 8.8§ 8.5§ 6.2‡ −0.11
(4.6 to 13.0) (4.4 to 12.5) (1.4 to 10.9) (−0.28 to 0.06)
SF36—role physical
tCBT 5.8‡ 5.7‡ 4.6 −0.05
(0.2 to 11.5) (0.3 to 11.1) (−2.0 to 11.2) (−0.31 to 0.21)
Exercise 4.4 4.3 3.5 −0.04
(−1.1 to 9.8) (−0.9 to 9.5) (−2.9 to 9.9) (−0.29 to 0.22)
Combined treatment 7.7‡ 8.0§ 9.8§ 0.08
(2.3 to 13.1) (2.8 to 13.1) (3.4 to 16.1) (−0.17 to 0.34)
SF36—vitality
tCBT 5.4‡ 5.4‡ 5.1 −0.01
(0.8 to 10.1) (0.9 to 9.8) (−0.3 to 10.5) (−0.22 to 0.19)
Exercise 2.6 2.7 4.0 0.06
(−1.9 to 7.0) (−1.5 to 7.0) (−1.2 to 9.3) (−0.14 to 0.26)
Combined treatment 5.0‡ 5.1‡ 5.5‡ 0.02
(0.6 to 9.4) (0.8 to 9.4) (0.3 to 10.7) (−0.18 to 0.22)
SF36—social function
tCBT 7.4‡ 7.4‡ 7.3‡ −0.01
(1.9 to 12.9) (2.2 to 12.6) (0.8 to 13.7) (−0.27 to 0.26)
Exercise 7.7‡ 7.0‡ 2.5 −0.22
(2.4 to 12.9) (2.0 to 12.0) (−3.8 to 8.7) (−0.47 to 0.04)
Combined treatment 6.7‡ 6.8‡ 7.8‡ 0.05
(1.4 to 11.9) (1.8 to 11.8) (1.6 to 14.0) (−0.21 to 0.30)
SF36—role emotional
tCBT 8.3§ 7.7§ 3.2 −0.21
(2.8 to 13.8) (2.5 to 12.8) (−3.4 to 9.7) (−0.49 to 0.07)
Exercise 9.1§ 8.8§ 6.4‡ −0.11
(3.9 to 14.4) (3.8 to 13.7) (0.1 to 12.8) (−0.38 to 0.16)
Combined treatment 8.0§ 7.1‡ 1.0 −0.29‡
(2.8 to 13.2) (2.2 to 12.0) (−5.3 to 7.4) (−0.56 to 0.02)
*The combined scales of the SF-36 are not available due to a printing error in the follow-up questionnaire.
†Comparison group is treatment as usual. Values are unstandardised coefficients with 95% CIs. All models are adjusted for age, sex, centre,
baseline CPG and GHQ scores, and baseline levels of outcome of interest.
‡p<0.05.
§p<0.004, with correction for multiple testing.
CPG, Chronic Pain Grade questionnaire; GHQ, General Health Questionnaire; tCBT, telephone cognitive behavioural therapy; SF-36, 36-item
Short Form Health Questionnaire.
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Table 6 Predictors of treatment effectiveness
Months post-treatment Longitudinal
adjusted model0* 3 24
Gender
Male vs female
TAU 1 1 1 1
tCBT 0.5 (0.1 to 3.9) 1.6 (0.2 to 11.5) 0.2 (0.0 to 1.5) 0.4 (0.1 to 2.1)
Exercise 0.6 (0.1 to 4.2) 0.8 (0.1 to 5.6) 0.2 (0.0 to 2.1) 0.4 (0.1 to 1.7)
Combined 0.5 (0.1 to 3.7) 0.8 (0.1 to 5.4) 0.2 (0.0 to 2.3) 0.4 (0.1 to 1.8)
CPG
3/4 vs 1/2
TAU 1 1 1 1
tCBT 1.2 (0.2 to 8.4) 3.5 (0.3 to 35.4) 11.8 (1.2 to 115.8) 4.8 (0.9 to 25.6)
Exercise 0.9 (0.1 to 6.2) 2.9 (0.3 to 30.0) 5.3 (0.5 to 52.5) 3.4 (0.6 to 17.9)
Combined 2.3 (0.0 to 15.1) 10.6 (1.1 to 105.6) 8.9 (0.9 to 86.8) 8.3 (1.6 to 43.4)
Age
Per 10 years
TAU 1 1 1 1
tCBT 1.3 (0.6 to 2.8) 1.1 (0.5 to 2.1) 1.5 (0.8 to 2.7) 1.2 (0.7 to 2.0)
Exercise 2.2 (1.1 to 4.6) 1.3 (0.7 to 2.7) 0.9 (0.5 to 1.7) 1.4 (0.8 to 2.2)
Combined 2.5 (1.2 to 5.1) 1.5 (0.8 to 3.0) 1.2 (0.7 to 2.2) 1.6 (0.98 to 2.6)
GHQ12
3–12 vs 0–2
TAU 1 1 1 1
tCBT 3.4 (0.5 to 20.8) 4.0 (0.7 to 23.0) 7.7 (1.5 to 40.7) 5.6 (1.5 to 21.2)
Exercise 0.8 (0.1 to 4.6) 1.7 (0.3 to 10.0) 4.5 (0.9 to 23.6) 2.3 (0.6 to 8.5)
Combined 1.5 (0.2 to 8.5) 1.5 (0.3 to 8.4) 6.7 (1.3 to 34.7) 3.2 (0.9 to 11.9)
Fatigue
19–40 vs 8–18
TAU 1 1 1 1
tCBT 0.6 (0.1 to 4.0) 0.7 (0.1 to 3.7) 1.7 (0.4 to 8.2) 1.0 (0.3 to 3.8)
Exercise 0.2 (0.0 to 1.7) 0.4 (0.1 to 2.6) 0.8 (0.2 to 4.0) 0.6 (0.2 to 2.1)
Combined 1.1 (0.2 to 7.8) 1.4 (0.3 to 8.0) 4.5 (0.9 to 21.8) 2.7 (0.7 to 9.6)
Passive coping
30–52 vs 18–29
TAU 1 1 1 1
tCBT 1.5 (0.2 to 10.3) 2.2 (0.4 to 12.8) 2.1 (0.4 to 10.4) 1.6 (0.4 to 5.7)
Exercise 1.0 (0.1 to 7.0) 0.5 (0.1 to 2.9) 1.1 (0.2 to 5.1) 0.8 (0.2 to 2.9)
Combined 3.7 (0.6 to 24.7) 2.2 (0.4 to 11.9) 1.6 (0.3 to 7.5) 2.1 (0.6 to 7.5)
Active coping
26–35 vs 10–25
TAU 1 1 1 1
tCBT 0.9 (0.1 to 5.5) 0.6 (0.1 to 3.5) 1.6 (0.3 to 7.1) 1.0 (0.3 to 3.4)
Exercise 2.2 (0.4 to 13.5) 1.5 (0.3 to 8.7) 1.7 (0.4 to 7.5) 1.7 (0.5 to 6.1)
Combined 0.7 (0.1 to 4.2) 0.6 (0.1 to 3.2) 0.3 (0.1 to 1.5) 0.7 (0.2 to 2.4)
Sleep problems
10–20 vs 0–9
TAU 1 1 1 1
tCBT 1.5 (0.2 to 9.3) 1.0 (0.2 to 5.9) 2.9 (0.6 to 14.1) 1.8 (0.5 to 6.5)
Exercise 1.9 (0.3 to 11.1) 2.1 (0.4 to 12.2) 2.5 (0.5 to 11.8) 2.4 (0.7 to 8.5)
Combined 1.2 (0.2 to 7.2) 0.9 (0.2 to 5.0) 1.0 (0.2 to 5.2) 1.1 (0.3 to 3.9)
TSK
37–57 vs 21–36
TAU 1 1 1 1
tCBT 2.0 (0.3 to 13.8) 3.7 (0.6 to 24.3) 10.6 (1.7 to 66.3) 4.7 (1.1 to 20.5)
Exercise 2.4 (0.4 to 16.3) 2.6 (0.4 to 17.3) 1.8 (0.3 to 11.8) 2.8 (0.7 to 12.1)
Combined 3.9 (0.6 to 26.6) 2.6 (0.4 to 16.6) 3.7 (0.6 to 23.1) 3.6 (0.8 to 15.1)
*ORs with 95% CIs.
Italic typeface indicates statistical significance.
CPG, Chronic Pain Grade questionnaire; GHQ, General Health Questionnaire; TAU, treatment as usual; tCBT, telephone cognitive
behavioural therapy; TSK, Tampa Scale for Kinesiophobia.
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Table 7 Estimated resource use, costs and utilities by treatment allocation group at 24 months post-treatment
TAU (N=109) CBT (N=112) Exercise (N=109)
CBT+exercise
(N=112)
N Mean SD N Mean SD N Mean SD N Mean SD
Intervention costs 0–6 months* 109 0 0 112 205 136 109 456 126 112 698 190
Routine health service costs to 3 months post-treatment* 67 837 1808 66 819 2112 76 807 1318 83 803 1320
Routine health service resource use (18–24 months)
GP visits 79 3.19 4.76 72 2.32 1.92 80 2.70 2.24 84 2.70 2.60
Practice nurse visits 79 1.22 2.21 72 1.76 5.72 80 1.16 1.91 84 1.13 1.88
Community physio visits 79 0.65 2.37 72 0.54 2.11 80 0.40 1.73 84 0.79 2.30
Other community visits 79 0.43 1.77 72 1.00 3.91 80 0.24 0.82 84 0.63 1.97
Outpatient visits 79 0.84 1.18 72 1.03 1.43 80 0.75 1.31 84 1.00 1.57
Hospital physio and other services 78 1.69 5.08 72 0.64 1.97 80 1.36 4.09 84 0.93 2.96
Inpatients’ admission days 79 0.29 1.24 72 0.30 0.94 80 0.71 1.99 84 0.76 2.26
Health service costs (18–24 months)
Primary care costs (18–24 months post-treatment) 79 £140 £185 72 £115 £124 80 £115 £97 84 £126 £135
Outpatient costs (18–24 months) 79 £99 £138 72 £120 £167 80 £90 £154 84 £117 £183
Hospital physio and other services (18–24 months post-treatment) 79 £97 £332 72 £39 £127 80 £80 £221 84 £82 £316
Hospital admissions costs (18–24 months post-treatment) 79 £181 £671 72 £254 £694 80 £452 £1184 84 £441 £1138
Total health service costs (18–24 months) 79 £516 £911 72 £529 £832 80 £737 £1382 84 £764 £1466
Imputed quarterly cost (3–18 months) 68 £206 £316 64 £248 £339 72 £317 £433 80 £308 £437
Total NHS costs (randomination—24 months post-treatment) 59 £2387 £3885 60 £2925 £3962 65 £3616 £3849 72 £3715 £4078
Utilities
EQ-5D baseline 108 0.649 0.216 112 0.730 0.151 108 0.686 0.209 111 0.681 0.175
EQ-5D 6 months 81 0.688 0.245 76 0.723 0.266 89 0.716 0.208 86 0.737 0.176
EQ-5D 9 months 83 0.645 0.262 71 0.754 0.214 81 0.705 0.238 90 0.701 0.220
QALYs (randomisation—3 months post-treatment) 67 0.516 0.144 64 0.548 0.141 71 0.539 0.122 78 0.537 0.110
EQ-5D (24 months post-treatment) 78 0.631 0.315 70 0.730 0.242 78 0.712 0.242 79 0.682 0.238
QALYs (randomisation—24 months post-treatment) 61 1.697 0.543 56 1.825 0.474 61 1.798 0.490 65 1.752 0.440
*Detailed breakdown of costs previously reported.
CBT, cognitive behavioural therapy; GP, general practitioner; NHS, National Health Service; QALY, quality adjusted life year; TAU, treatment as usual.
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adults with osteoarthritis, rheumatoid arthritis and ﬁbro-
myalgia.33 In our study, the only statistically signiﬁcant
difference between exercise and TAU at 2 years after
treatment, other than in patient perception of change
in their condition, was in the secondary measure SF-36
role emotional, an effect that did not persist after cor-
rection for multiple testing. Several guidelines on the
management of ﬁbromyalgia recommend the use of
multimodal therapy.34 35 We therefore hypothesised that
the beneﬁts of receiving exercise and tCBT for CWP
would be greater than either therapy alone. However, at
each follow-up, the effects on the primary outcome
measure of the combined therapy were very similar to
each intervention delivered alone. Nevertheless, it is
noteworthy that, compared with TAU, the most
statistically signiﬁcant differences for secondary outcome
measures occurred in the combined treatment group.
In summary, our study has demonstrated for the ﬁrst
time that a short course of either tCBT or exercise for
persons with CWP can result in long-term improvements
in patients’ global assessment of their condition, com-
pared with TAU. There does not appear to be substan-
tial advantage from providing both interventions. Our
work has identiﬁed features of patients who may be
more likely to respond to tCBT. Finally tCBT has been
shown not only to be effective but also highly
cost-effective. Future research should focus on: the
mechanism by which these improvements might occur;
identiﬁcation of which patients are likely to derive most
beneﬁt from these types of non-pharmacological inter-
ventions; and investigate novel ways of delivery to further
reduce the cost of provision.
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case data). CBT, cognitive behavioural therapy; QALY, quality
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